Wells Fargo
GTBP icon

Wells Fargo’s GT Biopharma GTBP Stock Holding History

Wells Fargo’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.83K Sell
15,986
-51
-0.3% -$21 ﹤0.01% 6131
2026
Q1 		$6.54K Hold
16,037
– – ﹤0.01% 6056
2025
Q4 		$12.6K Buy
16,037
+6,025
+60% +$4.28K ﹤0.01% 5901
2025
Q3 		$5.87K Hold
10,012
– – ﹤0.01% 6048
2025
Q2 		$35.8K Sell
10,012
-1
-0% -$3 ﹤0.01% 5619
2025
Q1 		$21.5K Hold
10,013
– – ﹤0.01% 5685
2024
Q4 		$30.5K Hold
10,013
– – ﹤0.01% 5637
2024
Q3 		$23.1K Hold
10,013
– – ﹤0.01% 5605
2024
Q2 		$28.3K Sell
10,013
-11
-0.1% -$39 ﹤0.01% 5487
2024
Q1 		$44.4K Hold
10,024
– – ﹤0.01% 5305
2023
Q4 		$76.7K Buy
10,024
+1
+0% +$7 ﹤0.01% 5069
2023
Q3 		$72.5K Buy
10,023
+6,670
+199% +$55.1K ﹤0.01% 4965
2023
Q2 		$31.4K Buy
3,353
+1
+0% +$10 ﹤0.01% 5607
2023
Q1 		$55.3K Hold
3,352
– – ﹤0.01% 5115
2022
Q4 		$89.1K Buy
3,352
+3,334
+18,522% +$167K ﹤0.01% 4595
2022
Q3 		$1K Sell
18
-2
-10% -$153 ﹤0.01% 6351
2022
Q2 		$2K Sell
20
-988
-98% -$74.9K ﹤0.01% 6322
2022
Q1 		$87K Buy
1,008
+653
+184% +$57.6K ﹤0.01% 5395
2021
Q4 		$32K Buy
355
+296
+502% +$44.3K ﹤0.01% 6167
2021
Q3 		$13K Buy
59
+46
+354% +$13.8K ﹤0.01% 6112
2021
Q2 		$6K Buy
13
+9
+225% +$3.74K ﹤0.01% 6282
2021
Q1 		$1K Buy
+4
New +$699 ﹤0.01% 6719

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Wells Fargo's GTBP Position: Q2 2026 in Review

Wells Fargo reduced its GT Biopharma (GTBP) stake by 0.32% in Q2 2026, selling an estimated $21 and leaving 15,986 shares worth $7.83K. The position accounts for ﹤0.01% of the portfolio, ranked #6131.

Wells Fargo first reported a position in GTBP in Q1 2021 and has held it in 22 quarters since. The position peaked at $89.1K in Q4 2022. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Wells Fargo held 15,986 shares of GT Biopharma worth $7.83K as of Q2 2026.
  • Wells Fargo sold 51 GT Biopharma shares in Q2 2026, an estimated $21.
  • GT Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6131 holding.
  • Wells Fargo first reported a position in GT Biopharma in Q1 2021 and has held it in 22 quarters since.
  • Wells Fargo's GT Biopharma position peaked at $89.1K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.